Loading market dashboard
Apogee Therapeutics, Inc.
APGEHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Apogee Therapeutics NASDAQ: APGE executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone.
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript
SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.
Apogee Therapeutics, Inc. remains a Buy, driven by zumilokibart's potential in atopic dermatitis and recent positive Phase 2b data. Zumilokibart's efficacy matches leading biologics, with the key differentiator being 2–4 annual doses, pending maintenance data in 2025. The Blackstone collaboration secures up to $1.3B in funding, eliminating near-term dilution risk and supporting commercialization.
Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic royalty financing with as much as $500 million in senior corporate debt, giving the immunology developer runway to advance Phase 3 development and potential commercialization of its lead candidate zumilokibart. The financing structure pairs royalty-based capital tied to future product revenue with senior debt capacity.
Blackstone (BX) is providing as much as $1.3 billion in financing to Apogee Therapeutics (APGE), giving the biotech company fresh capital to push zumilokibart t
Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026
SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m.
Apogee Therapeutics, Inc. has roughly doubled since October 2025, driven by promising data for the lead asset zumilokibart in atopic dermatitis. Zumi offers a significant compliance advantage with once-quarterly or twice-annual dosing, outperforming current biologics in efficacy and maintenance. Upcoming catalysts include Part B APEX data in 2Q26 and APG279 combination data in 2H26, with Phase 3 initiation and potential news vacuum thereafter.
Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year: - APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy over time with every 3- and 6-month dosing in moderate-to-severe AD - APEX Phase 2 Part B 16-week data in AD expected in Q2 2026 - Following positive Phase 1b asthma results earlier this year, expansion plans are underway with additional trial details for asthma and eosinophilic esophagitis (EoE) expected later this year Strong cash position of $1.3B following successful public equity offering extending runway into 2029, through planned BLA filing for AD, subject to regulatory alignment SAN FRANCISCO and BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today provided pipeline progress and reported first quarter 2026 financial results. “We are off to a rapid start in 2026, reflecting the team's relentless focus on execution.
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report)'s share price hit a new 52-week high on Wednesday. The stock traded as high as $89.63 and last traded at $88.47, with a volume of 559815 shares changing hands. The stock had previously closed at $86.74. Analysts Set New Price Targets Several analysts have recently weighed
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $82.58, for a total transaction of $1,651,600.00. Following the transaction, the chief executive officer owned 1,132,987 shares in
Aberdeen Group plc lessened its stake in Apogee Therapeutics Inc. (NASDAQ: APGE) by 34.1% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,103 shares of the company's stock after selling 18,657 shares during the quarter. Aberdeen Group plc owned approximately 0.05% of Apogee Therapeutics
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 750,000 additional shares, at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering were approximately $403 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.
The CEO of Apogee Therapeutics reported selling 20,000 shares of the company for approximately $1.50 million on March 11, 2026. This disposition represented 1.71% of Henderson's direct holdings at the time of the transaction, as reported in the Form 4.
Shares of Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $85.04 and last traded at $78.53, with a volume of 3533056 shares changing hands. The stock had previously closed at $73.00. More Apogee Therapeutics News Here are the
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering are expected to be approximately $350 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee. The offering is expected to close on March 26, 2026, subject to the satisfaction of customary closing conditions. In addition, Apogee has granted the underwriters an option for a period of 30 days to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and infrequent dosing boosting its promise.
Apogee Therapeutics, Inc. maintains a Strong Buy rating following positive 52-week maintenance data for zumilokibart in moderate-to-severe Atopic Dermatitis [AD]. APGE's half-life extended monoclonal antibody technology enables less frequent dosing, with Q3M and Q6M regimens showing EASI-75 responses of 75% and 85% in Week 16 responders. Upcoming catalysts include 16-week induction data from Part B of the phase 2 APEX trial in Q2 2026 and potential phase 3 initiation in H2 2026.
Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript
Apogee Therapeutics (APGE) remains a Buy, supported by strong Phase 2 data for zumilokibart in atopic dermatitis (AD) and a robust cash position. Zumilokibart's infrequent dosing (Q3M/Q6M) offers a key compliance advantage, with efficacy and safety comparable to market leaders and manageable side effects. My DCF model values APGE at $73.07/share, reflecting a $5B intrinsic equity value, though current market cap suggests limited near-term upside absent M&A.
SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has commenced an underwritten public offering of $300 million of shares of its common stock. In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock are being offered by Apogee.
The data revealed that zumilokibart demonstrated durable maintenance of response with both 3- and 6-month dosing regimens, with 75% and 85% of patients maintaining EASI-75, respectively.
Apogee Therapeutics reported a "best case scenario" Monday for its potential rival to eczema drug, Dupixent.
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients maintained vIGA 0/1 Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart
SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m.
